Project Grant HT94252410975
Award Date
11/1/24
Completion Date
10/31/26
Dollars Obligated
$162K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The University of Texas M.D. Anderson Cancer Center was awarded a $1,882,607 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) program on March 15, 2025. The grant supports advanced biomedical research to transform healthcare for military service members and the broader public, with a focus on leveraging prostate cancer's unique lipid metabolism to induce therapeutic ferroptosis. The research aims to advance disease...
The University of Texas MD Anderson Cancer Center was awarded a $1,214,999 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to identify collateral lethal targets in prostate cancer from September 1, 2021 through August 31, 2024. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,458,000.00 to The University of Texas MD Anderson Cancer Center to conduct research on "The Role of Androgens in Regulating Extracellular Vesicle Secretion and Molecular Cargo Loading by Prostate Cancer Cells." The 3-year project, beginning on March 1, 2024, aims to investigate how androgens, male sex hormones, influence the...
The University of Texas MD Anderson Cancer Center will receive $2,172,614 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. The Military Medical Research and Development program supports biomedical research with the goals of improving...
The University of Texas MD Anderson Cancer Center will receive $1,066,238 under a three-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will support research from September 2022 to September 2025 to develop an integrated genomic and therapeutic strategy for androgen-indifferent prostate cancers. Through basic, applied, and advanced biomedical research, the Military Medical Research and Development...
The Department of the Army Medical Command awarded a $249,999 Project Grant to The University of Texas M.D. Anderson Cancer Center through the Military Medical Research and Development program. This three-year grant will fund research from September 2022 to August 2025 to revisit antiangiogenic therapy and target prostate cancer metabolism. The Military Medical Research and Development program, designated by CFDA #12.420, supports basic, applied, and advanced biomedical research with the goals...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
This $1,306,991.00 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program will support research by The University of Texas M.D. Anderson Cancer Center to develop organoid-based models and therapeutic approaches targeting TP53-mutated acute myeloid leukemia. The research, spanning from August 1, 2025 to July 31, 2029, aims to advance understanding and treatment of this challenging cancer type with...
The University of Texas MD Anderson Cancer Center will receive $729,000 through a Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 2021 through August 2025 to translate novel discoveries in gastric adenocarcinoma biology into therapeutic advances. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to...